Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.7K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

741
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741
Angina IV: Management01:26

Angina IV: Management

493
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
493
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

1.9K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.9K
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

444
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
444
Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

2.4K
Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
2.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The GALENOS approach to triangulating evidence: a structured approach for integrating information from human and animal studies.

BMC medical research methodology·2026
Same author

Repurposed drug prioritization pipeline for a multi-arm platform trial in clinical Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Corrigendum to "Pro-dopaminergic pharmacological interventions for anhedonia in depression: a living systematic review and network meta-analysis of human and animal studies", EBioMedicine. 2025 Nov;121:105967. doi: 10.1016/j.ebiom.2025.105967.

EBioMedicine·2025
Same author

Pro-dopaminergic pharmacological interventions for anhedonia in depression: a living systematic review and network meta-analysis of human and animal studies.

EBioMedicine·2025
Same author

Developing treatments for cerebral small vessel disease: a scoping review of licensed interventions for potential repurposing.

F1000Research·2025
Same author

Testing the usefulness of a quality system in preclinical research.

Neuroscience applied·2025

Related Experiment Video

Updated: May 3, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.8K

Some salt with your statin, professor?

Malcolm Macleod1

  • 1Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom.

Plos Biology
|January 28, 2014
PubMed
Summary
This summary is machine-generated.

Pharmaceutical industry sponsorship of animal research on statins showed more conservative data but enthusiastic conclusions. This suggests potentially higher standards in industry-funded animal studies compared to other research areas.

More Related Videos

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.2K

Related Experiment Videos

Last Updated: May 3, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.8K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.2K

Area of Science:

  • Pharmacology
  • Biomedical Research
  • Drug Development

Background:

  • Pharmaceutical industry sponsorship in clinical trials is known to introduce biases, exaggerating benefits and minimizing harms.
  • The extent to which these biases affect non-human animal research remains an important question in scientific integrity.
  • Statins are a widely used class of drugs, making their research a relevant case study for industry influence.

Purpose of the Study:

  • To investigate potential biases in industry-sponsored non-human animal research, specifically concerning statins.
  • To compare the conclusions and data of industry-funded studies with those of non-industry-funded studies.
  • To understand the implications of industry sponsorship on the interpretation of animal research findings.

Main Methods:

  • Systematic review and meta-analysis were employed to synthesize existing research data.
  • Studies focused on statin research involving non-human animals were critically evaluated.
  • Comparison of conclusions and underlying data between industry-sponsored and non-industry-sponsored research was performed.

Main Results:

  • Industry-sponsored studies on statins presented more enthusiastic conclusions than the data strictly supported.
  • However, the actual data within industry-sponsored studies were more conservative than those in non-industry-sponsored studies.
  • This pattern suggests a complex interplay between investment return maximization and data interpretation.

Conclusions:

  • Industry-sponsored non-human animal research may exhibit different bias patterns compared to clinical trials, potentially indicating higher data standards.
  • Findings suggest a strategic approach by industry to secure robust data before clinical trials and to support favorable interpretations.
  • The academic research community may benefit from insights into the rigorous data practices observed in industry-funded animal research.